ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 310

The Trajectory of Grade 1 Erosions in the Feet of Patients with Early RA

Mary-Clair Yelovich1, Hanyan Zou1, Siobhan Deshauer1, Saara Totterman2, Karen A. Beattie3 and Maggie Larche4, 1McMaster University, Hamilton, ON, Canada, 2Qmetrics Technologies, Pittsford, NY, 3Medicine, McMaster University, Hamilton, ON, Canada, 4St Joseph's Healthcare Hamilton, Hamilton, ON, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Early Rheumatoid Arthritis, MRI and therapy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Imaging of Rheumatic Diseases Poster I: MRI

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The identification of erosions plays a critical role in the management of RA, as the presence of erosions denotes more aggressive disease requiring more aggressive treatment. MRI can be used to visualize and monitor erosion progression in RA, and is often used as a gold standard in research. While the clinical significance of grade 1 erosions remains unknown, so too does the trajectory of these erosions over time. This study examined the course of grade 1 erosions (involving 1-10% of bone on MRI) in the feet of newly diagnosed RA patients after two or more years of treatment.

Methods: Patients newly diagnosed with RA (treatment-naïve, ACR criteria) were recruited. Participants were assessed at baseline, 1-year, and ≥2 years (24-49 months) after diagnosis. The most clinically symptomatic foot chosen at baseline was scanned using a 1.0T peripheral MRI at each visit. A radiologist, blinded to clinical results, semi-quantitatively scored erosions in the metatarsal head and the base of the phalanges of each of MTPs 2-4 (grade 0-10) according to OMERACT-RAMRIS criteria. All patients were treated as per standard of care, and therapy received after baseline assessment was noted. The location of each erosion was noted to ensure that changes over time corresponded to the original erosion. Erosions were compared after one year and ≥2 years and categorized as unchanged, worsened or improved. New erosions were also noted.

Results: This study included 41 patients [n=33 females, mean (SD) age 51.9 (10.3) years]. The baseline MRI found at least one grade ≥1 erosion in 35 of 41 patients (85%), in 103 MTP joint bones. The majority of the erosions were grade 1 [n=89 (86%)] at baseline. Comparing grade 1 erosions one year later, 20 (19%) had resolved, 77 (75%) remained unchanged, 6 (6%) had progressed, and there were 20 new grade 1 erosions. Comparing baseline grade 1 erosions to ≥2 years later, 16 (16%) had resolved, 87 (84%) remained stable, 0 had progressed, and there were 10 new grade 1 erosions. Of note, only one erosion progressed by more than 1 grade within a follow-up period (grade 1 to grade 3 after 1 year). In terms of treatment, by their final assessment, 6 patients had received no DMARDs/biologics, 20 were on a single DMARD, 8 on combination DMARDs, and 7 on biologic or biologic/DMARD combination. There was no consistent relationship identified between the type of therapy and the improvement, stability, or progression of erosions.

Conclusion: Grade 1 erosions on MRI are common in the MTP joints of early RA patients. The majority of erosions appear to resolve or remain stable following two or more years of treatment. This suggests that early standard treatment may be sufficient to manage small erosions. There does not appear to be any consistent relationship between change in these small erosions and the type of RA treatment chosen. The clinical relevance of these erosions remains unknown.


Disclosure: M. C. Yelovich, None; H. Zou, None; S. Deshauer, None; S. Totterman, Qmetrics Technologies, 4; K. A. Beattie, None; M. Larche, AbbVie Inc., 2.

To cite this abstract in AMA style:

Yelovich MC, Zou H, Deshauer S, Totterman S, Beattie KA, Larche M. The Trajectory of Grade 1 Erosions in the Feet of Patients with Early RA [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/the-trajectory-of-grade-1-erosions-in-the-feet-of-patients-with-early-ra/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-trajectory-of-grade-1-erosions-in-the-feet-of-patients-with-early-ra/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology